6533b837fe1ef96bd12a1d67
RESEARCH PRODUCT
Apolipoprotein A1 in Cerebrospinal Fluid Is Insufficient to Distinguish Alzheimer's Disease from Other Dementias in a Naturalistic, Clinical Setting.
Patrick JungAndreas FellgiebelKristina EndresJohannes LotzMalena Dos Santos GuilhermeNicolai M Stoyesubject
Short CommunicationDiseasecerebrospinal fluidchemistry.chemical_compoundmedicineDementiaCognitive declinebiologyCholesterolbusiness.industryGeneral Neurosciencemedicine.diseasePsychiatry and Mental healthClinical PsychologychemistryCohortImmunologybiology.proteinBiomarker (medicine)biomarkerApolipoprotein A1lipids (amino acids peptides and proteins)Apolipoprotein A1Geriatrics and GerontologybusinessAlzheimer’s diseaseLipoproteindementiadescription
Apolipoprotein A1 (ApoA1) is the major protein component of the high-density lipoprotein and involved in cholesterol transport. Disruption of cholesterol homeostasis has been identified as a contributing factor for Alzheimer's disease (AD). Moreover, polymorphisms of ApoA1 have been associated with higher risk of disease onset and cognitive decline. Therefore, ApoA1 has been suggested as a biomarker in AD. Here, we tested a small cohort of AD and non-AD dementia patients and measured levels of ApoA1 in cerebrospinal fluid. Our results indicate that ApoA1 might not be applicable to distinguish AD from other forms of dementia.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-03-25 | Journal of Alzheimer's disease reports |